Purevax RCCh


vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Purevax RCCh has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

This EPAR was last updated on 22/01/2015

Authorisation details

Product details
Purevax RCCh
Agency product number
Active substance
  • attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)
  • inactivated feline calicivirosis antigens (FCV 431 and G1 strains)
  • attenuated Chlamydophila felis (905 strain)
International non-proprietary name (INN) or common name
vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Date of issue of marketing authorisation valid throughout the European Union
Contact address

29 Avenue Tony Garnier
69007 Lyon

Product information

12/02/2014 Purevax RCCh - EMEA/V/C/000092 - R/0007

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged 8 weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs and excretion;
  • against Chlamydophila felis infection to reduce clinical signs.

Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and Chlamydophila felis components.

The duration of immunity is 1 year after the last (re-)vaccination.

Assessment history

How useful was this page?

Add your rating